Cybersecurity Incident Management Commander

PepsiCo is closing a bottling plant in Cheverly, Maryland, after more than 60 years of operation, affecting 143 employees. The facility will cease manufacturing and warehouse operations on 13 November, though sales and delivery activities will continue. The company attributed the decision to changing consumer demand, technology, and network optimisation needs. Local officials noted the ageing facility had experienced power outages and maintenance issues. The closure is part of broader network changes. PepsiCo has recently shuttered facilities in Orlando, Rancho Cucamonga, Detroit, and Liberty, alongside four bottling plants in 2024, collectively impacting over 1,500 workers. Meanwhile, Coca-Cola plans a $10 billion investment in US infrastructure over the coming years, highlighting contrasting strategies in the evolving beverage market.

PepsiCo adds J&J chief Joaquin Duato to its Board. PepsiCo is bringing Johnson & Johnson's chairman and chief executive onto its board as an independent director from December 1, 2026, with a seat on the Audit Committee. PepsiCo has elected Johnson & Johnson Chairman and CEO Joaquin Duato to its Board of Directors as an independent director effective December 1, 2026, with a seat on the Audit Committee. PepsiCo (PEP) has elected Joaquin Duato, the chairman and chief executive of Johnson & Johnson (JNJ), to its Board of Directors. The appointment takes effect on December 1, 2026. Duato will serve as an independent director and will sit on the board's Audit Committee, according to the company's announcement as reported by GuruFocus. On the face of it, this is a routine governance filing: one name added to a long list. But the identity of the name and the committee he is joining say something about where PepsiCo believes its board needs more weight. A sitting chief executive of one of the largest healthcare companies in the world does not take on an outside directorship casually, and a food-and-beverage company does not recruit one by accident. What an audit seat actually involves. The Audit Committee is not a ceremonial posting. It is the committee that oversees the integrity of financial statements, the relationship with the external auditor, internal controls over financial reporting, and - at most large issuers - the framework for enterprise risk. Members are expected to be financially literate, and regulators in the United States require audit committees of listed companies to be composed entirely of independent directors. PepsiCo's disclosure that Duato joins as an independent director is therefore a prerequisite for the committee assignment, not a separate courtesy. Directors who run public companies themselves tend to be valued on audit committees for a practical reason: they have sat on the other side of the table. They have signed off on certifications, absorbed auditor findings, and had to explain restatements or control weaknesses to investors. For a consumer group with manufacturing and bottling operations across dozens of jurisdictions, that experience of complexity is the point. Why a healthcare chief executive fits a beverage board. The overlap between PepsiCo's business and Johnson & Johnson's is less strange than the sector labels suggest. Both are global, both are heavily regulated, both sell products consumers put in or on their bodies, and both run large-scale, compliance-intensive supply chains subject to inspection. Both also spend heavily on brands and face constant scrutiny of ingredient and labeling claims. More pointedly, the consumer staples industry is in the middle of a reformulation cycle. Sugar, sodium, portion sizes, artificial colors and the rise of appetite-suppressing medications have all pushed packaged food and drink companies toward products positioned nearer to health than indulgence. A director whose day job is running a pharmaceutical and medical technology company brings a specific kind of literacy to those conversations: how clinical evidence is generated, how regulators read claims, and how quickly public-health opinion can move against a category. There is also the organizational dimension. Running an enterprise of Johnson & Johnson's scale means managing portfolio decisions, separations and capital allocation across divisions that do not share the same growth profile. PepsiCo's structure - snacks and beverages, North America and international, owned and franchised bottling - poses a version of the same question about where capital earns its keep. The board arithmetic behind the appointment. Every outside director added to a mature consumer board changes the balance of the room slightly. Adding a serving chief executive changes it more than adding a retired one, because a serving executive is answerable to their own shareholders for how they spend their time and tends to arrive with a sharp view on operating discipline. Every outside director added to a mature consumer board changes the balance of the room slightly. Large consumer staples companies have spent recent years defending their multiples against slower volume growth, price-led revenue gains that consumers eventually resist, and competition from private label. Boards have responded by broadening the skills matrix they publish in proxy statements - adding directors with healthcare, technology, supply chain and capital markets backgrounds rather than only industry veterans. Duato's arrival reads as part of that pattern: a deliberate reinforcement of the audit and risk function at a moment when investors are asking harder questions about cost structures and portfolio shape. The effective date matters as well. A December 1, 2026 start means Duato is in place ahead of the annual reporting cycle, joining the Audit Committee in time for the work that precedes the publication of full-year results rather than arriving mid-stream. Where the two stocks stood at the last close. Governance appointments rarely move share prices, and there is no evidence this one did. As of the last trade on Thursday, September 17, 2026 at 20:00 GMT, PEP closed at 133.66, down 0.51% from the prior close of 134.34, having traded between 132.93 and 134.91 on the day. Johnson & Johnson finished at 270.22, up 1.10% from a prior close of 267.28, with a day range of 267.11 to 270.87. The broader tape was firmly higher in the same session. The S&P 500 tracker (SPY) closed at $762.60, up 1.13%; the Nasdaq 100 tracker (QQQ) ended at $716.92, up 1.73%; and the Dow 30 tracker (DIA) closed at $518.35, up 0.61%. PepsiCo's small decline against a broadly positive market is consistent with the defensive pattern of staples on risk-on days, when money rotates toward growth. It is not a verdict on the board announcement. What to watch from here. Three things are worth tracking. The first is PepsiCo's next proxy statement, which will set out Duato's committee memberships in full, his independence determination and his compensation as a non-employee director. The second is whether this appointment is a one-off or the opening move in a wider refresh - boards that add a heavyweight to the Audit Committee often follow with changes elsewhere, particularly on compensation and nominating committees. The third is Johnson & Johnson's own disclosure practice. Shareholders of any company whose chief executive takes an outside board seat pay attention to overboarding policies, and proxy advisers have grown less tolerant of sitting executives holding multiple external directorships. A single outside seat is well inside conventional limits, so the more interesting question is whether the healthcare group frames the role as a development opportunity or simply notes it. For PepsiCo investors, the practical read is modest but real: the company has strengthened the committee that guards its financial reporting with someone who has run a global, regulated, brand-driven enterprise at scale. That does not change the next quarter's volumes. It does change who is in the room when the harder questions about controls, risk and capital get asked. Key facts. * New director: Joaquin Duato, Chairman and CEO of Johnson & Johnson * Effective date: December 1, 2026 * Role: Independent director; member of the Audit Committee * PEP last close: 133.66, -0.51% (as of Sep 17, 2026, 20:00 GMT) Frequently asked questions. Who is joining PepsiCo's board? Joaquin Duato, the chairman and chief executive officer of Johnson & Johnson, has been elected to PepsiCo's Board of Directors. He will serve as an independent director and as a member of the board's Audit Committee. PepsiCo said the appointment takes effect on December 1, 2026. What does the Audit Committee do? An audit committee oversees the integrity of a company's financial statements, the work and independence of the external auditor, internal controls over financial reporting, and typically the broader risk management framework. For US-listed companies, audit committee members must be independent of management and financially literate. Does an independent director mean he has no ties to PepsiCo? Independence is a formal determination made by the board under exchange listing standards. It means the director has no material relationship with the company - no employment, no significant commercial dealings, no compensation beyond director pay - that would compromise their judgment on behalf of shareholders. How did PepsiCo shares trade around the announcement? As of the last trade on September 17, 2026 at 20:00 GMT, PEP closed at 133.66, down 0.51% from the prior close of 134.34, within a day range of 132.93 to 134.91. That was against a rising market, with the S&P 500 tracker up 1.13% and the Nasdaq 100 tracker up 1.73% on the day. Where did Johnson & Johnson stock close? Johnson & Johnson shares finished at 270.22 as of the September 17, 2026 close, a gain of 1.10% from the prior close of 267.28. The day range was 267.11 to 270.87. Duato's outside directorship at PepsiCo is a governance matter and has no direct bearing on that price move. Why would a food and beverage company want a healthcare executive on its board? Packaged food and drink companies face the same pressures healthcare firms know well: heavy regulation, inspection-intensive manufacturing, scrutiny of product claims and shifting public-health opinion. A healthcare chief executive brings experience in evidence-based product positioning, global compliance and allocating capital across divisions with different growth profiles.